Background: Krebs von den Lungen-6 (KL-6), predominantly expressed by type II alveolar cells, is linked to the prognosis and severity of interstitial lung disease (ILD). This investigation sought to ...
The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results